Cervical Cancer Reagents | abinScience

Home > Featured Products > Oncology Research > Cervical Cancer

Virtually all cervical cancers are HPV-driven. Beyond HPV detection and p16 surrogate testing, PD-1 checkpoint inhibitors and emerging ADCs are expanding treatment options for advanced disease. abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO

Key Biomarkers & Targets

HPV

Human Papillomavirus

HPV E6/E7 drive cervical carcinogenesis; L1 is the vaccine target. 130 products. Validated: Blocking, ELISA, IHC, WB.

Antibodies • Biosimilars • Proteins

p16 / CDKN2A

Tumor Suppressor

p16 overexpression is the IHC surrogate for HPV integration. 55 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.

Antibodies • Biosimilars • Proteins

PD-L1

CD274

Pembrolizumab approved for PD-L1+ cervical cancer. 130 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.

Antibodies • Biosimilars • Proteins

TROP2

TACSTD2

ADC target being evaluated in cervical cancer. 32 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

Nectin-4

PVRL4

ADC target being evaluated in cervical cancer. 29 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

VEGF

Angiogenesis

Bevacizumab backbone of cervical cancer combination therapy. 122 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

B7-H3 / CD276

Immune Checkpoint

Overexpressed in cervical SCC; emerging target. 39 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

EGFR

ErbB1

EGFR pathway in cervical cancer. 108 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

Why Researchers Choose abinScience

IHC-Validated AntibodiesAntibodies with IHC validation available for: HPV, p16, PD-L1, TROP2, Nectin-4, VEGF. See individual product pages for clone details and recommended dilutions.

Flow Cytometry ReadyFC-validated antibodies available for: p16, PD-L1, TROP2, Nectin-4, VEGF, B7-H3. Multiple conjugates (FITC, APC, PE, PerCP) offered for select clones.

Research-Grade BiosimilarsBiosimilar-grade reference proteins with ELISA and FACS validation for: HPV, p16, PD-L1, TROP2, Nectin-4.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

IHC-based biomarker detection: We offer IHC-validated antibodies for HPV, p16, PD-L1, TROP2, Nectin-4. See product pages for validated species and recommended dilutions.
Flow cytometry immunophenotyping: FC-validated antibodies available for p16, PD-L1, TROP2, Nectin-4, VEGF. Select clones offered in FITC, APC, PE, and PerCP conjugates.
Functional and blocking assays: Antibodies with blocking/neutralization validation available for: HPV, p16, PD-L1, VEGF.
Biosimilar comparability: Research-grade biosimilar proteins (ELISA/FACS/Functional assay validated) available for HPV, p16, PD-L1, TROP2.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

What HPV reagents do you offer?

We offer 100 detection antibodies, 1 research-grade biosimilar proteins, and 29 recombinant proteins. Validated applications include: Blocking, ELISA, IHC, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), SAA2229 (ELISA, IHC, WB; unconjugated), SAA2454 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Anti-HPV18 L1/Major capsid protein L1 An).

What PD-L1 reagents do you offer?

We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).

What VEGF reagents do you offer?

We offer 66 detection antibodies, 39 research-grade biosimilar proteins, and 17 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A169 (ELISA, IHC, WB; unconjugated), YW64.3 (ELISA, FC; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Vesencumab, Navicixizumab, Dilpacimab).

What EGFR reagents do you offer?

We offer 45 detection antibodies, 49 research-grade biosimilar proteins, and 14 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: SAA2220 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), 11F8 (ELISA, FC, WB; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Modotuximab, Tomuzotuximab, Depatuxizumab).

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.

496 product results for "Cervical Cancer"

Options+